Heart Attacks, Strokes Follow Insurance Rejection
What happens when high-risk heart patients can’t get the cholesterol-lowering medicine their doctor prescribes? Heart attacks and strokes, new data confirms.
Second Annual Cardiovascular Health Policy Summit
Sandeep Jauhar’s grandfather was sitting down to lunch with family when he crumpled to the floor. Jeff Kwitowski’s father was on a routine bike ride. Cat Davis Ahmed’s father was enjoying a game of tennis. And Florence Champagne was in an office building when she dropped to her knees, gasping for air and praying for […]
Cardiovascular Summit Spotlights Stories of Access Barriers, Risk and Heart Health
Sandeep Jauhar’s grandfather was sitting down to lunch with family when he crumpled to the floor.
UK Study Reinforces Need for Personalized Treatment Plans
High cholesterol? For most patients, that means starting a statin regimen. But now research suggests that it may be time to embrace a more nuanced approach to lowering LDL levels.
What Heart Attack & Stroke Mean to EU Workplaces
Heart attack and stroke don’t just affect patients across Europe, new research reveals.
What Heart Patients’ Experience Teaches Us about Pharmacy Benefit Managers
On April 9, a congressional hearing will explore the impact of pharmacy benefit managers on high drug prices.
What EU Parliamentary Candidates Need to Know about Heart Health
As the European Union edges toward parliamentary elections, patient advocates have a message for candidates: Prioritize heart health.
IfPA Report Card: Health Plans Reject 1 in 3 High-Risk Heart Patients
Suffered a heart attack? Diagnosed with cardiovascular disease? Confirmed you have genetic high cholesterol? None of that may matter to your health plan. As new data reveals, insurers are still saying “no” to patients whose physicians prescribe a cholesterol-lowering PCSK9 inhibitor. Even one in three at-risk patients who meet traditional criteria for coverage. […]
PCSK9 Inhibitors: National Report Card
A national data supplier reviewed PCSK9 inhibitor claims for Medicare, Medicaid, Medicaid managed care, and commercial managed care organizations across the nation from January 2018 through December 2018. Of national health plans that received at least 3,000 claims for PCSK9 inhibitors, the following had the highest rates of rejection: Federal Employee Benefit Plan – 76% […]
New “Fast Facts” Highlights Impact of High Cholesterol on Europe
More than 50 percent of Europeans have raised cholesterol, increasing their risk of heart attack, stroke and death – and costing the EU billions every year in health care expenses and lost productivity. So explains a new “Fast Facts” policy brief from the European Alliance for Patient Access, a division of the Global Alliance for Patient Access.
